Shares of Cellectar Biosciences, Inc. (NASDAQ:CLRB – Get Free Report) passed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $3.30 and traded as low as $2.30. Cellectar Biosciences shares last traded at $2.37, with a volume of 548,187 shares traded.
Cellectar Biosciences Stock Down 3.2 %
The company has a market cap of $82.10 million, a P/E ratio of -0.74 and a beta of 0.98. The company’s 50-day moving average is $2.80 and its two-hundred day moving average is $3.29.
Cellectar Biosciences (NASDAQ:CLRB – Get Free Report) last posted its quarterly earnings data on Tuesday, May 14th. The biopharmaceutical company reported ($0.40) EPS for the quarter, beating the consensus estimate of ($0.50) by $0.10. On average, analysts anticipate that Cellectar Biosciences, Inc. will post -1.51 EPS for the current fiscal year.
Institutional Inflows and Outflows
About Cellectar Biosciences
Cellectar Biosciences, Inc, a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer.
Further Reading
- Five stocks we like better than Cellectar Biosciences
- Roth IRA Calculator: Calculate Your Potential Returns
- Why Call Options Volume for These 2 Stocks Spiked Together
- High Dividend REITs: Are They an Ideal Way to Diversify?
- MarketBeat Week in Review – 7/22 – 7/26
- Investing in Travel Stocks Benefits
- 3M Surprises and Rebound Accelerates: It Isn’t Too Late To Get In
Receive News & Ratings for Cellectar Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectar Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.